You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物大升近15%,金斯瑞升近5%!業內人士解釋CRO拉昇原因
港A兩地CRO板塊集體拉昇,其中,港股市場藥明生物大升近15%,藥明康德升9%,康龍化成升超7%,凱萊英和方達控股升超5%,泰格醫藥和金斯瑞升近5%,昭衍新藥升超3%。消息面上,盤前有傳言稱,涉及藥明生物和藥明康德的HR8333提案在納入NDAA立法過程中受阻。但有業內分析人士稱:“其實藥明法案靴子真正落地要看7月到11月的幾個流程,昨晚的NDAA大家不是很在意。目前的拉昇應該主要還是受益於於位置低,有資金藉機嘗試去做反彈。”

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.